Related Experiment Video
Updated: Jan 30, 2026
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Identification of CD320, SLC44A1 and TNFRSF13B as potential novel therapeutic targets for CAR T-cell therapy in
Francesca Garofano1, Anna Maria Corsale2, Marta Biondo3
1Laboratory of Experimental Hematology and Immunogenomics, University Hospital of Palermo, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Hematology Unit, University of Palermo, Palermo, Italy.
Introduction:
Multiple myeloma (MM) remains incurable despite effective therapies, with most patients eventually relapsing. Chimeric antigen receptor (CAR) T-cell therapy has improved treatment options but is limited by antigen escape and lack of durable responses. To expand the spectrum of actionable antigens, we sought to identify novel CAR-T actionable targets.
Methods:
We analyzed 11 publicly available single-cell RNA sequencing datasets from patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering MM (SMM), MM, relapsed/refractory MM (RRMM) and healthy donors. Plasma cell-specific surface proteins were identified via bioinformatic filtering and validated on external bulk transcriptomic database of ~2,000 patients and by flow cytometry on MM cell lines and primary bone marrow samples.
Results:
We identified 15 plasma cell-associated surface proteins, including BCMA, CD138, CD38, and SLAMF7. Five molecules-TNFRSF13B (TACI), CD59, FCGR2B (CD32B), SLC44A1 (CD92), and CD320-were prioritized for further study. CD320 and SLC44A1 were upregulated with disease stage and associated with poor survival, while TNFRSF13B, CD59, and FCGR2B were enriched in advanced disease and linked to better outcomes. Cytogenetic clustering linked these molecules to specific genetic backgrounds, suggesting subtyperelated expression patterns. Flow cytometry confirmed the surface expression of CD59, SLC44A1, TNFRSF13B and CD320.
Discussion:
CD320, SLC44A1, and TNFRSF13B are promising, clinically relevant targets for CAR T-cell therapy in MM. Their stage-specific expression and prognostic significance support their potential to enhance existing immunotherapeutic strategies.
Insights
Researchers identified novel targets for CAR T-cell therapy in multiple myeloma (MM). CD320, SLC44A1, and TNFRSF13B show promise for enhancing immunotherapies in MM patients, offering new hope against this incurable cancer.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Multiple myeloma (MM) is an incurable plasma cell malignancy with frequent relapse.
- Current Chimeric Antigen Receptor (CAR) T-cell therapies face challenges like antigen escape and limited durability.
- Novel therapeutic targets are crucial to expand treatment options for MM.
Purpose of the Study:
- To identify and validate novel cell surface protein targets for CAR T-cell therapy in multiple myeloma.
- To assess the expression patterns and prognostic significance of potential targets across different disease stages.
Main Methods:
- Analysis of 11 single-cell RNA sequencing datasets from various stages of plasma cell disorders and healthy donors.
- Bioinformatic filtering to identify plasma cell-specific surface proteins.
- Validation using bulk transcriptomic data, flow cytometry on cell lines, and primary bone marrow samples.
Main Results:
- Fifteen plasma cell-associated surface proteins were identified, including BCMA, CD138, CD38, and SLAMF7.
- Five molecules (TNFRSF13B, CD59, FCGR2B, SLC44A1, CD320) were prioritized.
- CD320 and SLC44A1 showed upregulation with disease stage and poor survival correlation.
- TNFRSF13B, CD59, and FCGR2B were enriched in advanced disease and linked to better outcomes.
- Surface expression of CD59, SLC44A1, TNFRSF13B, and CD320 was confirmed by flow cytometry.
Conclusions:
- CD320, SLC44A1, and TNFRSF13B represent promising, clinically relevant targets for CAR T-cell therapy in multiple myeloma.
- Their stage-specific expression and prognostic value suggest potential for improving existing immunotherapeutic strategies in MM.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:58Cell Potential and Free Energy
Thermodynamics is the branch of physics dealing with the relationship between heat and other forms of energy. In an electrochemical cell, chemical energy is converted into electrical energy.
Thus, a link can be predicted between cell potential, free energy change, and the equilibrium constant for the reaction. Cell potential can also be measured as the oxidant or the reducing strength, and similar acid-base strength measures are reflected in equilibrium...
00:59Gene Therapy
01:49Multiple Allele Traits
01:13Therapeutic Index
00:52Potential Energy
Chemical bonds that form attractive forces between atoms also contain potential energy, called chemical energy. When a chemical reaction...